Business Context and Reporting Period
Company: American Vanguard Corp.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 1995
Industry: Agricultural Chemicals (Producer of Bidrin, Naled, PCNB, Phosdrin, Metam Sodium)
Key Financial Metrics
| Metric | Q1 1995 | Q1 1994 |
|---|---|---|
| Net Sales | $10,134,300 | $7,726,100 |
| Gross Profit | $3,831,800 | $3,111,500 |
| Gross Margin | 38% | 40% |
| Operating Income | $113,700 | $169,500 |
| Net Loss | $(77,500) | $(58,000) |
| Loss Per Share | $(0.03) | $(0.02) |
| Cash Flow from Operations | $(137,800) | $919,800 |
| Working Capital | $4,255,500 | N/A |
| Total Debt (Current + Long-term) | $13,601,100 | N/A |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 31% ($2.4 million) driven by higher sales of Bidrin, Naled, and PCNB, which offset a significant decline in Phosdrin sales.
- Margin Compression: Gross profit margin declined from 40% to 38% due to a shift in sales mix, specifically the phase-out of Phosdrin (sales dropped from $2.4M to $366K).
- Operating Expenses: Increased by $776,100 (26%) due to higher selling expenses (royalties/rebates), increased R&D costs for product registration, shipping costs, and the opening of a new European office in the UK.
- Cash Flow: Operating cash flow turned negative ($137,800 outflow) compared to a positive $919,800 in the prior year, primarily due to reductions in accounts payable and accrued expenses.
Outlook, Risks, and Management Commentary
- Product Phase-out: The company is complying with EPA agreements to phase out the domestic distribution and sale of Phosdrin, impacting product mix and margins.
- Liquidity: Working capital decreased by $417,200 to $4.26 million. The company has a $10.5 million secured line of credit with $900,000 availability as of March 31, 1995.
- Debt Maturity: The line of credit was extended from April 30, 1995, to May 31, 1995. Management expects renewal but is exploring alternate financing sources to maintain flexibility.
- Seasonality: Management notes that quarterly results vary significantly due to weather, crop cycles, and product mix. First-quarter results historically contribute a smaller percentage of annual revenue.
Investor Verification Checklist
- Verify the renewal status of the $10.5 million line of credit maturing May 31, 1995.
- Monitor the impact of the Phosdrin phase-out on future gross margins and revenue stability.
- Assess the return on investment for the new European office and increased R&D spending.
- Review the trend in operating cash flow, which turned negative in Q1 1995 despite revenue growth.
- Confirm the timeline for the reduction of Phosdrin inventory and receivables related to the discontinued product.